AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

ISM9546Positive

AI Analysis

Summary

Insilico Medicine nominated ISM9546, an oral peripheral-restricted VAV1 degrader, as a preclinical candidate for autoimmune diseases. This marks the company's 35th PCC nominated since 2021 and its 11th in 2026, demonstrating continued AI-driven R&D productivity.

Outcome Details

Preclinical candidate nomination

Importance:4/10

Sentiment:

0.60

AI-driven drug discoverymolecular glueVAV1 degraderoral therapyperipheral-restrictedpipeline milestonepreclinical

Related Companies

$MOLN $SHWZ $TRAX

Read the original article

Published by PR Newswire Pharma on October 13, 2026 1:00 PM

Read Original